Lantheus Sets October 14 Vote on $8B Curium Acquisition With $12/Share CVR Upside
LNTH has more than doubled off its 52-week low of $49.67.
Summary
Definitive proxy sets October 14 vote on the $8B Curium acquisition, detailing the full CVR milestone structure worth up to $12/share and the $81M Morgan Stanley fee.
Key Events · M&A and Partnerships · LNTH
-
Special Meeting Set for October 14
Stockholders of record as of September 1, 2026 will vote on the merger agreement, advisory compensation, and adjournment proposals at a virtual-only meeting.
-
CVR Milestone Structure Quantified
Eight milestones across prostate cancer ($950M-$1.75B in 2030 sales), neurology ($300M-$350M in 2028-2030), and DEFINITY ($400M in 2030) could pay up to $12 per share in aggregate.
-
Morgan Stanley Fee Disclosed
Financial advisor to receive approximately $81 million total, with $10.5 million payable on opinion delivery and the remainder contingent on closing.
-
Termination Fee Structure
Lantheus pays $228 million if it accepts a superior proposal; Parent pays $385 million general or $100 million regulatory termination fee.
Analysis · LNTH · Life Sciences
The definitive proxy for the $8 billion Curium acquisition has been filed, locking in an October 14, 2026 special meeting date and revealing the full CVR milestone structure that could add up to $12 per share on top of the $102.50 cash consideration. Eight commercial milestones across prostate cancer, neurology, and DEFINITY franchises are quantified, with prostate cancer products needing to hit $950 million to $1.75 billion in 2030 adjusted sales to trigger payments. Morgan Stanley's fairness opinion fee of approximately $81 million and the termination fee structure ($228 million from Lantheus, $385 million from Parent) are now public. The deal remains subject to stockholder approval and regulatory clearances including HSR, German FCO, and Swedish FDI review, with closing expected in the first half of 2027.
How filings like this one have moved
In the 30 days to Sep 8, 2026, 45.2% of the 628 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, LNTH was trading at $100.97 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.6B. The 52-week trading range was $49.67 to $111.86. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.